Form 4: Vaxart SVP, Chief Scientific Officer Sean Tucker Reports Acquisition of 406,000 Shares and Grant of Stock Options

Sean Tucker, SVP, Chief Scientific Officer of Vaxart, Inc., reports acquiring 406,000 shares of common stock and being granted options to purchase 610,000 shares.

Summary

• On March 24, 2025, Sean Tucker, the SVP, Chief Scientific Officer of Vaxart, Inc., acquired 406,000 shares of common stock.
• These shares were granted upon the vesting of restricted stock units.
• Tucker also received a stock option to purchase 610,000 shares of common stock at an exercise price of $0.5126.
• 25% of the shares underlying the stock option will vest on March 24, 2026, and the remainder will vest in 36 equal monthly installments, making the option fully vested on March 24, 2029.
• Following these transactions, Tucker directly owns 744,403 shares of common stock.
• Tucker also indirectly owns 51,465 shares through joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The vesting of shares and grant of options could be seen as mildly positive, indicating confidence in the company's future.

Positives

• The vesting of restricted stock units and grant of stock options to a key executive like the Chief Scientific Officer can be seen as a positive sign, aligning their interests with the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options indicates a multi-year commitment from the executive.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and executive compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
• Companies like Moderna and BioNTech also utilize stock options and restricted stock units as part of their compensation strategy for key personnel.
• The vesting schedules and exercise prices are generally structured to reward long-term value creation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it demonstrates the executive's increased stake in the company.
• Employees may view the vesting of shares and grant of options as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Vaxart, Sean Tucker, stock options, restricted stock units, beneficial ownership, Form 4, VXRT, insider trading